Haemonetics Corporation

HAE trades at a remarkably compressed 14.6 P/E despite sitting just 39.4 on the RSI—well below the 50 midpoint—suggesting the market has already priced in material pessimism. With only 5.78% short interest and the stock nowhere near its 52-week high, there's minimal forced-covering risk, but the RSI reading indicates oversold conditions without the typical capitulation-reversal setup. The medical device sector trades at higher multiples, making this valuation potentially attractive if execution improves, though the subdued momentum warns that sentiment remains fragile and any positive catalyst would need genuine operational confirmation to sustain a rebound.